{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:16:19Z","timestamp":1777889779447,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jacl.2026.04.005","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:15:12Z","timestamp":1775754912000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipoprotein(a) in selected autoimmune diseases: A systematic review of cardiovascular implications and anti-inflammatory interventions"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-0118","authenticated-orcid":false,"given":"Efrain Miguel","family":"Castillo-C\u00f3rdoba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0226-4223","authenticated-orcid":false,"given":"Alekhya","family":"Mitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1261-5785","authenticated-orcid":false,"given":"Francisco Jos\u00e9","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jacl.2026.04.005_bib1","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.005_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.jacl.2026.04.005_bib3","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","article-title":"2025 Heart Disease and Stroke Statistics: a report of US and Global Data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2026.04.005_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001247","article-title":"Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis","volume":"6","author":"Yazdany","year":"2020","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.005_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102925","article-title":"Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus","volume":"21","author":"Restivo","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jacl.2026.04.005_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.974826","article-title":"Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: a path to potential biomarkers","volume":"13","author":"Guzman-Martinez","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.005_bib7","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.jacl.2026.04.005_bib8","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10459","key":"10.1016\/j.jacl.2026.04.005_bib9","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.04.005_bib10","article-title":"Role of lipoprotein (A) in aortic valve stenosis: novel disease mechanisms and emerging pharmacotherapeutic approaches","volume":"55","author":"Khan","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"20","key":"10.1016\/j.jacl.2026.04.005_bib11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jacl.2026.04.005_bib12","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jacc.2024.05.058","article-title":"The off-treatment effects of olpasiran on lipoprotein(a) lowering: OCEAN(a)-DOSE extension period results","volume":"84","author":"O'Donoghue","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.04.005_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.04.005_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/480784","article-title":"A systematic literature review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis","volume":"2012","author":"Missala","year":"2012","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.jacl.2026.04.005_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119244","article-title":"Association of lipoprotein(a) with cardiovascular events among individuals with autoimmune conditions","volume":"406","author":"Alebna","year":"2025","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.jacl.2026.04.005_bib16","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1177\/09612033221111958","article-title":"Lipoprotein(a) in systemic lupus erythematosus is associated with history of proteinuria and reduced renal function","volume":"31","author":"Connolly","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.jacl.2026.04.005_bib17","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2026.04.005_bib18","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst Rev"},{"key":"10.1016\/j.jacl.2026.04.005_bib19","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: Ottawa Hospital Research Institute; 2013. Available at https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed April 28, 2026."},{"issue":"7","key":"10.1016\/j.jacl.2026.04.005_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00380-024-02508-0","article-title":"Clinical characteristics and risk factors of cardiovascular disease in systemic lupus erythematosus patients","volume":"40","author":"Liao","year":"2025","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jacl.2026.04.005_bib21","first-page":"187","article-title":"TNF inhibitors exert a \"hidden\" beneficial effect in the cardiovascular lipoprotein profile of RA patients","volume":"16","author":"Calvo Alen","year":"2022","journal-title":"Biologics"},{"issue":"5-6","key":"10.1016\/j.jacl.2026.04.005_bib22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.clinbiochem.2006.11.018","article-title":"Lipoprotein (a) and apolipoprotein (a) in primary antiphospholipid syndrome","volume":"40","author":"Becarevic","year":"2007","journal-title":"Clin Biochem"},{"issue":"2","key":"10.1016\/j.jacl.2026.04.005_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40744-021-00419-4","article-title":"Primary antiphospholipid syndrome with and without acute myocardial infarction\/angina: a cross-sectional study","volume":"9","author":"de Carvalho","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"9","key":"10.1016\/j.jacl.2026.04.005_bib24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/metabo13090976","article-title":"Lipid metabolism traits mediate the effect of psoriasis on myocardial infarction risk: a two-step mendelian randomization study","volume":"13","author":"Ding","year":"2023","journal-title":"Metabolites"},{"issue":"12","key":"10.1016\/j.jacl.2026.04.005_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23966","article-title":"Serum concentrations of small dense low-density lipoprotein cholesterol and lipoprotein(a) are related to coronary arteriostenosis in Takayasu arteritis","volume":"35","author":"Chen","year":"2021","journal-title":"J Clin Lab Anal"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.005_bib26","first-page":"67","article-title":"Lipoprotein (a) and nitrites in Behcet's disease: relationship with disease activity and vascular complications","volume":"16","author":"Esmat","year":"2006","journal-title":"Eur J Dermatol"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.005_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/112067210101100112","article-title":"Lipoprotein (a) in Behcet's disease as an indicator of disease activity and in thrombotic complications","volume":"11","author":"Gurbuz","year":"2001","journal-title":"Eur J Ophthalmol"},{"issue":"8","key":"10.1016\/j.jacl.2026.04.005_bib28","first-page":"473","article-title":"Plasma lipoprotein(a) and its relationship with disease activity in patients with Behcet's disease","volume":"33","author":"Orem","year":"1995","journal-title":"Eur J Clin Chem Clin Biochem"},{"issue":"9","key":"10.1016\/j.jacl.2026.04.005_bib29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1136\/ard.54.9.726","article-title":"Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behcet's disease","volume":"54","author":"Orem","year":"1995","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.jacl.2026.04.005_bib30","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/01.ATV.18.6.984","article-title":"Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures","volume":"18","author":"Ramharack","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.jacl.2026.04.005_bib31","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/jcm12072529","article-title":"Lipoprotein (a), inflammation, and atherosclerosis","volume":"12","author":"Di Fusco","year":"2023","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.jacl.2026.04.005_bib32","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"Muller","year":"2015","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.jacl.2026.04.005_bib33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacl.2026.04.005_bib34","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2026.04.005_bib35","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41569-024-01045-7","article-title":"Autoimmune diseases and atherosclerotic cardiovascular disease","volume":"21","author":"Porsch","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"6144","key":"10.1016\/j.jacl.2026.04.005_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jacl.2026.04.005_bib37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"issue":"24","key":"10.1016\/j.jacl.2026.04.005_bib38","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1016\/j.jacc.2024.08.059","article-title":"High lipoprotein(a) as a cause of kidney disease: a population-based mendelian randomization study","volume":"84","author":"Bay Simony","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.04.005_bib39","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2020\/e1801","article-title":"Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis","volume":"75","author":"Ding","year":"2020","journal-title":"Clinics"},{"issue":"3","key":"10.1016\/j.jacl.2026.04.005_bib40","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jacl.2026.04.005_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.12.003","article-title":"Lipoprotein(a) at the crossroads of inflammation and atherosclerosis in rheumatoid arthritis: A narrative review","author":"Yuliasih","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2026.04.005_bib42","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"5-6","key":"10.1016\/j.jacl.2026.04.005_bib43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.cca.2009.12.008","article-title":"Detection of serum beta(2)-GPI-Lp(a) complexes in patients with systemic lupus erythematosus","volume":"411","author":"Zhang","year":"2010","journal-title":"Clin Chim Acta"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426001042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426001042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:17:44Z","timestamp":1777612664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426001042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":43,"alternative-id":["S1933287426001042"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.04.005","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) in selected autoimmune diseases: A systematic review of cardiovascular implications and anti-inflammatory interventions","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}